Plot No.367, Abhey Pur, Industrial Area Phase-1, Panchkula, Haryana 134109
Don't miss out on this limited-time offer to join our successful PCD Pharma network. Fill in your details below and our team will get in touch with you to discuss the best franchise opportunities tailored to your needs.
Cephalexin (125mg) DT
Therapeutic Category
Antibacterials, Antibiotic, General and OTC medicines, Pediatrics
Dosage Form
Tablet
Packaging Type
Strip Pack
Packaging
10*10
Price
₹121/-
High-resolution images and Product visuals
Product overview and usage information
Detailed information and research documents
Fixolexin 125 DT Tablet is an antibiotic formulation containing Cephalexin, a first-generation cephalosporin. It is widely used for the treatment of bacterial infections, specifically those caused by susceptible Gram-positive and Gram-negative bacteria. Cephalexin works by inhibiting bacterial cell wall synthesis, effectively stopping bacterial growth and proliferation. This tablet is ideal for treating respiratory infections, urinary tract infections, skin infections, and soft tissue infections, among others.
The Fixolexin 125 DT Tablet is designed with dispersible technology (DT), ensuring easy dissolution in water, making it suitable for individuals who may have difficulty swallowing whole tablets, such as children and elderly patients. Its fast-dissolving formulation enhances patient compliance, ensuring the antibiotic reaches its therapeutic effect quickly and efficiently.
Common side effects include nausea, vomiting, diarrhea, and abdominal discomfort. Rare allergic reactions may include rash, swelling, or itching.
Fixolexin 125 DT Tablet is indicated for treating respiratory tract infections, urinary tract infections, skin and soft tissue infections, otitis media, and other bacterial infections.
Do not use if allergic to cephalosporins or penicillin. Complete the full course of treatment as prescribed, even if symptoms improve.
Store in a cool, dry place away from moisture and direct sunlight. Keep out of reach of children.
Composition : Cephalexin (750mg) ER
Composition : Cefuroxime (500mg)
Composition : Cefuroxime (250mg)
Composition : Cefpodoxime Proxetil (200mg) + Ofloxacin (200mg)
Composition : Cefpodoxime Proxetil (200mg) + Clavulanic Acid (125mg)
Composition : Cefpodoxime Proxetil (200mg)
Composition : Cefpodoxime Proxetil (100mg)
Composition : Cefixime (400mg)
Composition : Cefixime (200mg) + Sulbactam (150mg)
Composition : Cefixime (200mg) + Ofloxacin (200mg)
This catalog is a digital representation of the Cafoli Lifecare portfolio and is intended for use by authorized pharmaceutical distributors and PCD franchise partners.
Cephalexin 125 mg DT is a first-generation cephalosporin antibiotic used for the treatment of bacterial infections such as respiratory tract infections, skin and soft tissue infections, urinary tract infections, ear infections, and dental infections, especially in pediatric patients. Being a dispersible tablet (DT), it is easy to administer in children, making it a strong pediatric anti-infective segment product.
Medical distributors and wholesalers can benefit from high and consistent prescription demand from pediatricians, general physicians, and hospitals. Antibiotics like cephalexin are widely prescribed for common infections, ensuring steady monthly sales and strong retail turnover.
Yes, Cafoli Lifecare offers PCD pharma pharma franchise opportunities in anti-infective, pediatric, and general medicine segments with monopoly rights, quality manufacturing standards, and reliable supply support for distributors and medical agencies.
Wholesalers and medical agencies benefit from high prescription volume, strong pediatric infection demand, and continuous antibiotic usage in outpatient settings, making it a fast-moving and stable pharmaceutical category when partnered with Cafoli Lifecare.
Medical distributors, stockists, and pharma professionals interested in pediatric antibiotic formulations can contact Cafoli Lifecare to discuss product availability, pricing structure, and PCD pharma franchise opportunities in the anti-infective and pediatric segment.